LEADER 04242nam 2201057z- 450 001 9910557129503321 005 20231214133253.0 035 $a(CKB)5400000000040759 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68363 035 $a(EXLCZ)995400000000040759 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCannabis$eNeuropsychiatry and Its Effects on Brain and Behavior 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (204 p.) 311 $a3-03943-995-2 311 $a3-03943-996-0 330 $aOver the years, there has been increasing interest into the public health impact of cannabis use, especially by young adults. This follows the evidence of a growing prevalence of regular cannabis use worldwide, with approximately 200 million users. Recreational cannabis use, especially a frequent use of products with high levels of its main psychoactive ingredient delta-9-tetrahydrocannabinol (? 9-THC), can cause dependence and have transient and long-lasting detrimental mental health effects, also negatively impacting cognitive processing and brain function and metabolism. In regular users, the development of tolerance to some of the effects of cannabis, especially the pleasurable ones, may lead to progressively heavier use in order to obtain the same effects in terms of their intensity, with higher health risks. However, the Cannabis Sativa plant contains different chemicals with different potential effects. In this regard, cannabidiol has gained interest because of its potential therapeutic properties, in line with evidence that CBD and ?9-THC may exhibit opposite effects at the cannabinoid receptor type 1 (CB1), ?9-THC being a partial agonist and CBD an antagonist/inverse agonist. Different cannabinoids may modulate human brain function and behavior in different ways, with different risk?benefit profiles. 517 $aCannabis 606 $aMedicine$2bicssc 606 $aNeurosciences$2bicssc 610 $adelta-9-tetrahydrocannabinol 610 $aplacebo 610 $acannabis-associated psychosis 610 $aschizophrenia 610 $aBDNF 610 $aCB1 610 $aCB2 610 $aepisodic memory 610 $aexercise 610 $aAfrican American 610 $ablack 610 $aolder adult 610 $amarijuana use 610 $acannabis use disorder 610 $acue reactivity 610 $acraving 610 $ainhibitory control 610 $afrontal alpha asymmetry 610 $aEEG 610 $acannabinoids 610 $acannabis use 610 $apsychotic disorder 610 $agenetics 610 $aage of onset 610 $aclinical high risk 610 $acannabis 610 $amemory 610 $afunctional magnetic resonance imaging 610 $aTHC 610 $asystematic review 610 $agyrification 610 $asurface area 610 $acortical surface structure 610 $aaerobic fitness 610 $agender 610 $aendocannabinoid system 610 $aexecutive functions 610 $aproblematic cannabis use 610 $atriple network 610 $aEEG functional connectivity 610 $aeLORETA 610 $aresting state 610 $aDelta-9-tetrahydrocannabinol 610 $adronabinol 610 $amarijuana 610 $arandomized controlled trial 610 $aopioids 610 $atraumatic injury 610 $aalcohol 610 $aadolescents 610 $afMRI 610 $ainteroception 610 $anegative reinforcement 610 $amigraine: chronic pain 610 $atriptans 610 $adisability 615 7$aMedicine 615 7$aNeurosciences 700 $aColizzi$b Marco$4edt$01291839 702 $aBhattacharyya$b Sagnik$4edt 702 $aColizzi$b Marco$4oth 702 $aBhattacharyya$b Sagnik$4oth 906 $aBOOK 912 $a9910557129503321 996 $aCannabis$93021984 997 $aUNINA